NOVAVAX AB

Their core work

NOVAVAX AB is a Swedish vaccine biotechnology company based in Uppsala whose web presence (isconova.com) points to ISCONova — a company known for developing ISCOM-based immune-stimulating complex adjuvant technology. In both H2020 projects, they contributed adjuvant formulation and antigen presentation expertise to large, internationally coordinated malaria vaccine consortia. Their technical work spans multiple parasite life-cycle stages — sporozoite, liver, blood-stage, and transmission-blocking — covering both Plasmodium falciparum and Plasmodium vivax, the two principal malaria species. They function as a specialist platform technology provider: consortia bring them in for their proprietary adjuvant and antigen-display systems rather than for general vaccine research capacity.

What they specialise in

How they've shifted over time

Both H2020 projects were launched in 2017, so the temporal window is narrow, but the keyword pattern still reveals a meaningful thematic shift. The first project (OptiMalVax) centers on Plasmodium falciparum with a technically dense multi-antigen, multi-stage approach using SpyCatcher VLP technology — the more established and heavily funded malaria vaccine target. The second project (MultiViVax) pivots entirely to Plasmodium vivax, a species responsible for the majority of malaria cases outside Africa but which has historically received far less vaccine investment. This suggests a deliberate strategy to broaden their malaria vaccine portfolio to cover both major Plasmodium species rather than concentrating exclusively on falciparum.

Their expansion from falciparum to vivax suggests growing engagement with global health funders and LMIC-focused vaccine programs — a direction that aligns with current WHO priorities and opens doors to Gavi, CEPI, and PATH-linked consortia.

How they like to work

NOVAVAX AB has never served as a coordinator in H2020 — they join exclusively as participants, which is the classic pattern of a technology-platform company that provides a specific enabling component rather than managing research programs. Their 20 consortium partners across 7 countries in just two projects shows they were embedded in large, multi-partner international consortia, typical of the major EU malaria vaccine grants where 10–20 institutions share a single award. Working with them likely means procuring a specific adjuvant or antigen-display service rather than entering a long-term co-design relationship.

Despite only two projects, NOVAVAX AB reached 20 unique consortium partners across 7 countries — an unusually broad footprint for a two-project participant, reflecting the large multi-institutional structure of EU global health vaccine grants. No single-country or regional concentration is evident from the data.

What sets them apart

NOVAVAX AB occupies a narrow but high-value niche: adjuvant and antigen formulation technology applied to some of the most complex vaccine targets in global health. The mismatch between their CORDIS name (NOVAVAX AB) and web presence (isconova.com) points to ISCONova's ISCOM-Matrix adjuvant platform — a technology that later underpinned Novavax's COVID-19 vaccine — giving them credibility well beyond what two modest EU grants suggest. For a consortium builder, this is not a generalist research partner but a specific technology node: if you need adjuvant expertise or VLP-based antigen display for an infectious disease vaccine program, this is a rare Swedish asset.

Highlights from their portfolio

• OptiMalVax
  The largest of their two projects (EUR 150,000) and the most technically ambitious, combining four malaria parasite stages with SpyCatcher VLP antigen display — one of the most complete multi-stage P. falciparum vaccine attempts in H2020.
• MultiViVax
  Targets Plasmodium vivax, the globally prevalent but historically neglected malaria species, signaling a strategic move into an underfunded but growing area of global vaccine development.